Description of the medicine: Dexrazoxane (Dexrazoxane)
(+) - (S) -1,4-propylene di-2,6-piperazinedione.
Synonym: Cardioxan, Cardioxan.
White crystalline powder. It is soluble in water.
The cyclic analogue of EDTA (ethylenediaminetetraacetic acid).
It forms chelating bonds with iron and copper salts.
It violates the formation of the doxorubicin-iron complex (and other anthracycline antibiotics with iron), and also prevents the appearance of iron-containing free radicals that mediate the cardiotoxicity of anthracycline antitumor antibiotics.
Assign for the prevention of cardiomyopathy with the use of anthracycline antitumor antibiotics.
It is administered intravenously dropwise to adults at a dose of 0.5 g / m 2 (0.5 g is dissolved in 0.167 M sodium lactate solution to a concentration of 10 mg / ml or in 0.9% sodium chloride solution or 5% glucose solution to a concentration of 1.3 -5 mg / ml) 30 minutes before the intravenous administration of doxorubicin at a dose of 50 mg / m 2 or (Scheme II) at a dose of 1 g / m 2 (0.5 g is dissolved in 25 ml of water for injection, then in Ringer's solution of lactate or sodium lactate up to 250-500 ml) for 45-60 minutes before the administration of doxorubicin (first 20-30 minute infusion, then a 20-30 minute break). Bred ex tempore. The solution is suitable for 6 hours after preparation.
Possible side effects: dyspepsia, alopecia, leukopenia, thrombocytopenia, pain at the injection site.
The drug is contraindicated in pregnancy and lactation.
Release form: lyophilized powder for injection solutions in 0.5 g vials complete with solvent.
Storage: List B.